Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835208 | 1.00 | SCN9A (0.56) | SCN9ASCN1ASCN5ASCN8A | |
| SCHEMBL1094279 | 0.87 | SCN9A (0.57) | SCN9ASCN5A | |
| SCHEMBL29669015 | 0.84 | SCN9A (0.59) | SCN9ASCN1ASCN5ASCN8A | |
| SCHEMBL20238716 | 0.84 | SCN9A (0.59) | SCN9ASCN1ASCN5ASCN8A | |
| SCHEMBL29835199 | 0.83 | SCN9A (0.55) | SCN9ASCN1ASCN5ASCN8A | |
| SCHEMBL1094585 | 0.82 | SCN9A (0.55) | SCN9ASCN1ASCN5ASCN8A | |
| SCHEMBL18885650 | 0.79 | SCN9A (0.56) | SCN9ASCN5A | |
| SCHEMBL29835172 | 0.79 | SCN9A (0.47) | SCN9ASCN1ASCN5ASCN8A | |
| SCHEMBL30479367 | 0.79 | SCN9A (0.55) | SCN9ASCN1ASCN5ASCN8A | |
| SCHEMBL16108028 | 0.78 | SCN9A (0.57) | SCN9ASCN1ASCN5ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108290881-B | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2021-12-07 | — | — | CN | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| EP-2773641-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2013064984-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SCN1A 23/4885SCN5A 19/4885 |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPV3, TRPV2 | SCN9A 40/4885SCN1A 12/4885SCN5A 26/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SCN1A 23/4885SCN5A 19/4885 |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | SCN9A 39/4885SCN1A 20/4885SCN5A 24/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SCN1A 23/4885SCN5A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.